nChroma Bio
Healthcare & Life Sciences
Recent Finacing
Equity
Recent Raise
$75M
nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.
Focus Areas
Epigenetic editing
Genetic medicines
Non-viral delivery
Liver-targeted therapy
Chronic hepatitis B and D
Programmable tissue specificity
Investors